EXEL vs RPRX
Exelixis vs Royalty Pharma plc — AI-powered side-by-side comparison
VS
RPRX
Royalty Pharma plc
56
Watch
| Metric | EXEL | RPRX |
|---|
| AI Score |
67
|
56
|
| Price |
$51.30
|
$57.79
|
| P/E Ratio |
15.60×
|
23.98×
|
| ROE |
36.2%
|
11.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
96.5%
|
89.4%
|
| Debt / Equity |
0.09×
|
1.31×
|
| Dividend Yield |
0.0%
|
1.6%
|
| RSI (14) |
41.0
|
49.6
|
| Beta |
0.422
|
0.425
|
| Expected Upside |
+8.7%
|
—
|
AI Committee View
Current Innellis committee reasoning for EXEL versus RPRX.
EXEL leads by 11 points.
EXEL scores 67/100 (Buy) versus RPRX at 56/100 (Watch).
EXEL Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. The main limiting factor is price-to-book of 5.4x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 42.5% shows genuine earnings power backing the valuation — Value
- EPS growing 52.7% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- Price-to-book of 5.4x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
RPRX Committee View
60% agreement
5 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Value Analyst remains cautious — p/e of 40.9 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- P/E of 40.9 is expensive by classic value standards — Value
- EPS declining -15.9% YoY despite any revenue growth — Growth
- MACD histogram negative -- bearish momentum — Technical